Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18469522 | 0.85 | ALDH1A1 (0.34) | LMNAHTR2CALDH1A1 | |
| SCHEMBL435089 | 0.78 | LMNA (0.49) | LMNAPOLBSMN1; SMN2PKMMEN1 | |
| SCHEMBL17193796 | 0.75 | LMNA (0.34) | LMNAHTR2CTP53POLBSMN1; SMN2 | |
| SCHEMBL25070406 | 0.73 | CYP2D6 (0.37) | LMNATP53SMN1; SMN2PKMMEN1 | |
| SCHEMBL18469498 | 0.73 | CYP2D6 (0.37) | LMNATP53SMN1; SMN2PKMMEN1 | |
| SCHEMBL8473812 | 0.73 | HTR2C (0.34) | LMNAHTR2CTP53POLBSMN1; SMN2 | |
| SCHEMBL18469483 | 0.72 | CCR8 (0.36) | HTR2CALDH1A1 | |
| SCHEMBL12301088 | 0.72 | PDK2 (0.35) | LMNAHTR2CTP53POLBSMN1; SMN2 | |
| SCHEMBL8469239 | 0.71 | POLB (0.33) | LMNAHTR2CTP53POLBSMN1; SMN2 | |
| SCHEMBL19954245 | 0.71 | POLB (0.33) | LMNAHTR2CTP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | LMNA 3101/4885HTR2C 1269/4885TP53 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.